Bone Formation Regulates Circulating Concentrations of Fibroblast Growth Factor 23
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
We examined the role of bone remodeling in the regulation of circulating concentrations of FGF23 using mouse models manifesting differing degrees of coupled and uncoupled bone turnover. Administration of the antiresorptive agent osteoprotegerin produced a profound reduction in bone resorption and formation in male and oophorectomized female mice, accompanied by an increase in serum levels of fibroblast growth factor 23 (FGF23) and a reduction in circulating 1,25-dihydroxyvitamin D [1,25(OH)2D]. In contrast, exogenous PTH(1-34) administration increased bone turnover and reduced circulating FGF23. In 1,25(OH)2D-deficient, 25-hydroxyvitamin D 1α-hydroxylase null mice on a high-calcium diet, endogenous PTH was elevated, bone formation but not resorption was increased, and serum FGF23 was virtually undetectable; on a rescue diet, serum calcium was normalized, PTH levels were reduced, bone formation was reduced, and serum FGF23 levels increased. After PTH treatment of wild-type mice, gene expression of dentin matrix protein 1 (DMP1) in bone was increased, whereas gene expression of FGF23 was reduced. In vitro studies in the osteoblastic cell line UMR-106 showed that externally added DMP1 could inhibit FGF23 gene expression and production stimulated by 1,25(OH)2D3. The results show that osteoblastic bone formation is a potent modulator of FGF23 production and release into the circulation, suggest that the biological consequences on mineral homeostasis of circulating FGF23 may also be dependent on the prevailing rate of bone turnover, and provide evidence that DMP1 may be a direct negative regulator of FGF23 production in osteoblastic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602 · cited 2×
“Increased turnover was induced by administering exogenous PTH(1-34) (34).”
BackgroundFeng, J. Q., Ward, L. M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S. I., Zhang, S., et al. (2006) · Nature Genetics · doi:10.1038/ng1905 · Cited by 1,199 · cited 2×
“Increased turnover was induced by administering exogenous PTH(1-34) (34).”
BackgroundEndocrine functions of bone in mineral metabolism regulation
Quarles, L. D. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36479 · Cited by 459 · cited 1×
“DMP1 appeared to be a likely candidate to mediate this response (48).”
BackgroundBai, X., Miao, D., Li, J., Goltzman, D., & Karaplis, A. C. (2004) · Endocrinology · doi:10.1210/en.2004-0233 · Cited by 329 · cited 3×
“Increased turnover was induced by administering exogenous PTH(1-34) (34).”
BackgroundSelf-citationYao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
Samadfam, R., Xia, Q., & Goltzman, D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060915 · Cited by 80 · cited 1×
“The doses selected were consistent with those that had been reported to reduce bone resorption in mice or rats in vivo and that have been previously used by us (36, 37).”
BackgroundSelf-citation
Cited by
Regulation and Function of the FGF23/Klotho Endocrine Pathways
Martin, A., David, V., & Quarles, L. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00002.2011 · Cited by 594
Update on fibroblast growth factor 23 in chronic kidney disease
Wolf, M. (2012) · Kidney International · doi:10.1038/ki.2012.176 · Cited by 391
Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease
Wolf, M. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121293 · Cited by 308
Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease
Quarles, L. D. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.027 · Cited by 298
FGF23 and its role in X-linked hypophosphatemia-related morbidity
Beck-Nielsen, S. S., Mughal, Z., Haffner, D., Nilsson, O., Levtchenko, E., Ariceta, G., de Lucas Collantes, C., Schnabel, D., Jandhyala, R., & Mäkitie, O. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1014-8 · Cited by 278
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism
Quarles, L. D. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.218 · Cited by 269
Fibroblast Growth Factor 23 and Inflammation in CKD
Munoz Mendoza, J., Isakova, T., Ricardo, A. C., Xie, H., Navaneethan, S. D., Anderson, A. H., Bazzano, L. A., Xie, D., Kretzler, M., Nessel, L., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13281211 · Cited by 267
Rhee, Y., Bivi, N., Farrow, E., Lezcano, V., Plotkin, L. I., White, K. E., & Bellido, T. (2011) · Bone · doi:10.1016/j.bone.2011.06.025 · Cited by 262
Martin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J. Q., & Quarles, L. D. (2011) · The FASEB Journal · doi:10.1096/fj.10-177816 · Cited by 254
Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway
Rowe, P. S. N. (2012) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i1.50 · Cited by 173
Quinn, S. J., Thomsen, A. R. B., Pang, J. L., Kantham, L., Bräuner-Osborne, H., Pollak, M., Goltzman, D., & Brown, E. M. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2012 · Cited by 115
Self-citation
Metadata
- Authors
- Samadfam, R., Richard, C., Nguyen-Yamamoto, L., Bolivar, I., & Goltzman, D.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2009-10-09
- Volume
- 150
- Issue
- 11
- Pages
- 4835-4845
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2061659182
- Cited by
- 106
- References
- 6
- FWCI
- 8.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.